IDO Inhibitor/Chemo Combo Shows Early Promise in Advanced Pancreatic Cancer
April 27th 2016
Nathan Bahary, MD, discusses results of a study that showed that the combination of indoximod with standard chemotherapy yielded a response rate of 42% as a first-line therapy for patients with metastatic pancreatic adenocarcinoma.